Avanir Pharmaceuticals Inc. reported today new, positive results for their leading drug, AVP-923, designed to treat agitation in Alzheimer's disease patients. The results will be presented at the American Neurological Association's (ANA) 2014 Annual Meeting in Baltimore, MD, October 12-14, 2014. Joao Siffert, MD, chief medical officer at Avanir, said, "With no FDA-approved drugs for the treatment of agitation in Alzheimer's disease, we believe these results represent a breakthrough for patients. We are extremely excited with the prospect of bringing a potential treatment that can provide clinically meaningful relief to these patients and reduce caregiver burden. These study results represent the second neuropsychiatric disorder where AVP-923 has shown benefit and lends support for further advancement of our research programs into related disorders." Alzheimer's patients often exhibit behavioral and psychiatric symptoms, which may include paranoia, wandering, hallucinations (seeing, hearing, or feeling things that are not there), restlessness, irritability, and confusion. As a result, Alzheimer's patients usually feel anxious or agitated. Currently in America, 5.4 million people suffer from Alzheimer's disease. Without any cure, the drugs available can only temporally treat Alzheimer's patients' symptoms.